Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis

Childhood interstitial lung disease (chILD) comprises a spectrum of rare diffuse lung disorders. chILD is heterogeneous in origin, with different disease manifestations occurring in the context of ongoing lung development. The large number of disorders in chILD, in combination with the rarity of eac...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2019-11, Vol.200 (10), p.1219-1227
Main Authors: Deterding, Robin R, DeBoer, Emily M, Cidon, Michal J, Robinson, Terry E, Warburton, David, Deutsch, Gail H, Young, Lisa R
Format: Article
Language:English
Subjects:
Child
Child, Preschool
Childhood
Clinical trials
Clinical Trials as Topic
Concise Clinical Review
Humans
Idiopathic Pulmonary Fibrosis - diagnosis
Idiopathic Pulmonary Fibrosis - therapy
Lung Diseases, Interstitial - diagnosis
Lung Diseases, Interstitial - therapy
Medical diagnosis
Pediatrics
Pulmonary fibrosis
Research Design
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Childhood interstitial lung disease (chILD) comprises a spectrum of rare diffuse lung disorders. chILD is heterogeneous in origin, with different disease manifestations occurring in the context of ongoing lung development. The large number of disorders in chILD, in combination with the rarity of each diagnosis, has hampered scientific and clinical progress within the field. Epidemiologic and natural history data are limited. The prognosis varies depending on the etiology, with some forms progressing to lung transplant or death. There are limited treatment options for patients with chILD. Although U.S. Food and Drug Administration-approved treatments are now available for adult patients with idiopathic pulmonary fibrosis, no clinical trials have been conducted in a pediatric population using agents designed to treat lung fibrosis. This review will focus on progressive chILD disorders and on the urgent need for meaningful objective outcome measures to define, detect, and monitor fibrosis in children.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201903-0544CI